003000.KS लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 12:00):

Stats
आज की मात्रा	97 884.00
औसत मात्रा	689 294
बाजार मूल्य	408.25B
EPS	KRW0 ( 2024-04-22 )
अगली कमाई की तारीख	( KRW0 ) 2024-05-13
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW7.24 (0.12%)

मात्रा सहसंबंध

लंबा: -0.02 (neutral)

छोटा: -0.54 (weak negative)

Signal:(46.978) Neutral

Bukwang Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Bukwang Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

0.58
( weak )

0.03
( neutral )

-0.30
( neutral )

0.06
( neutral )

0.26
( neutral )

0.43
( neutral )

Bukwang Pharmaceutical वित्तीय

Annual	2023
राजस्व:	KRW125.93B
सकल लाभ:	KRW50.05B (39.74 %)
EPS:	KRW-457.67

FY	2023
राजस्व:	KRW125.93B
सकल लाभ:	KRW50.05B (39.74 %)
EPS:	KRW-457.67

FY	2022
राजस्व:	KRW190.91B
सकल लाभ:	KRW79.43B (41.61 %)
EPS:	KRW-62.07

FY	2021
राजस्व:	KRW182.49B
सकल लाभ:	KRW75.76B (41.51 %)
EPS:	KRW-8.74

Financial Reports:

No articles found.

Bukwang Pharmaceutical

Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.